Hormone therapyFDA-approvedSecond-line
Abiraterone
How it works
Blocks the production of testosterone in the body, which can slow cancer growth.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 65% of patients achieved an objective response, with a median overall survival of approximately 15 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median prostate cancer-specific survival from the initiation of DTX was 16.1 months in the ENZ-DTX group and 25.3 months in the ABI-DTX group. | Source → |
| Olaparib + Abiraterone for Metastatic Prostate Cancer: Real-World Study | Prostate Cancer | preclinical | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | phase-2 | The 1-year radiographic progression-free survival rate was 77.7% (95% CI: 63.4-95.3%). | Source → |
| Study Examines Effectiveness of Prostate Cancer Treatments in Patients with History of Other Cancers | Prostate Cancer | phase-3 | Within the HOC+ group, OS was significantly worse with ENZ than with ABI (median 16.0 vs. 30.5 months; HR 3.27; 95% CI 1.08-9.89; p = 0.0354) | Source → |
| Evaluating a New Medicine for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Abiraterone, Apalutamide, and Prednisone in Treating Hormone-Naive Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Men with Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 38.6 months in the niraparib + AAP group versus 8.3 months in the placebo + AAP group. | Source → |
| Testing Xaluritamig Plus Abiraterone for Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Low-Dose Abiraterone May Be a Feasible Alternative for Prostate Cancer Treatment | Prostate Cancer | phase-3 | Median PSA-PFS was 5.7 months with low-dose versus 3.8 months with standard-dose AA. | Source → |
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Testing a New Treatment for Advanced Prostate Cancer | Prostate Cancer | phase-1 | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone Acetate May Help Fight Prostate Cancer by Triggering Stress Response | Prostate Cancer | lab-study | AA induced concentration/time-dependent cytotoxicity in LNCaP cells (24 h IC₅₀ = 4.8 μM) and 22Rv1 cells (24 h IC₅₀ = 15.2 μM) and proliferation decreased by 54.1% and 7.3% at 4.8 μM, respectively. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Combining Medications May Help Prostate Cancer Patients | Prostate Cancer | phase-3 | The primary endpoint was met, with a significant improvement in radiographic progression-free survival observed, with a hazard ratio of 0.63. | Source → |
| Combining Trastuzumab Deruxtecan and Abiraterone Shows Promise in Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| New Delivery System for Prostate Cancer Treatment Shows Promise | Prostate Cancer | lab-study | The dissolution study demonstrated significantly higher ABT release from ABT-ssSNEDDS in comparison to free ABT after 2 h in pH 1.2 and 6.8 pH buffer. | Source → |
| Comorbidities Affect Abiraterone Treatment in Prostate Cancer | Prostate Cancer | meta-analysis | — | Source → |
| Modified Monitoring of Abiraterone May Reduce Liver Damage in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Comparing Prostate Cancer Treatments: Abiraterone, Enzalutamide, and Apalutamide | Prostate Cancer | observational | Abiraterone was significantly better in 99% PSA decline achievement compared to apalutamide (72% vs. 57%, p = 0.003). | Source → |
| Abiraterone Resistance in Prostate Cancer Linked to CENPK Splice Variant | Prostate Cancer | lab-study | — | Source → |
| Olaparib and Abiraterone Combination Therapy for Prostate Cancer | Prostate Cancer | review | — | Source → |
| Abiraterone Treatment in Prostate Cancer: Early Response Matters | Prostate Cancer | phase-2 | Those patients with hetero-responding disease had significantly different PFS compared to the responding and non-responding groups (hazard ratio: responding group = reference, hetero-responding group = 4.0, non-responding group = 5.8; p < 0.0001). | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | observational | Patients initiating enzalutamide had a 0.90-month longer overall survival compared to those initiating abiraterone acetate at 4 years. | Source → |
| Long-term effects of prostate cancer treatment studied | Prostate Cancer | phase-2 | A significant association between higher abiraterone acetate concentrations and better clinical benefit was observed (p = 0.041). | Source → |
| Abiraterone Efficacy Predicted by Prostate Cancer Biomarker | Prostate Cancer | observational | The median PSA-PFS was 11.43 months versus 26.43 months in patients with KI67 ≥ 30% versus those with KI67 < 30%. | Source → |
| Abiraterone May Cause Heart Rhythm Problem in Some Patients | Prostate Cancer | observational | — | Source → |
| New Treatment Combination for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median radiographic progression-free survival was 25 months for olaparib plus abiraterone versus 17 months for placebo plus abiraterone. | Source → |
| New Study Compares Effectiveness of Two Cancer Drugs for Prostate Cancer | Prostate Cancer | phase-3 | The median PSA response rate was -65.4% with abiraterone and -78.8% with enzalutamide. | Source → |
| Genetic variant linked to poorer prostate cancer treatment outcomes | Prostate Cancer | observational | A total of 54 patients (20%) had the variant, which was associated with a significantly worse overall survival (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and time to progression (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038). | Source → |
| Radiation Therapy and Medication Combination Shows Promise for Prostate Cancer | Prostate Cancer | phase-2 | Biochemical response was detected in 79.6% of patients in the experimental arm, compared to 68.3% in the control arm. | Source → |
| Abiraterone Acetate May Be Better Than Docetaxel for Prostate Cancer | Prostate Cancer | observational | The abiraterone acetate group demonstrated significantly better progression-free survival (PFS) than the docetaxel group (not reached vs. 15.1 months: hazard ratio = 0.37; 95% confidence interval = 0.28-0.50; P < .001). | Source → |
| New Study Links Certain Prostate Cancer Drugs to Cardiovascular Risks | Prostate Cancer | observational | — | Source → |
| New Hormonal Agents May Help Some Prostate Cancer Patients | Prostate Cancer | phase-3 | AAP seems to be effective in improving OS among patients with VM (hazard ratio, HR: 0.58, 95% CI, 0.40-0.84, P = .004 for AAP). | Source → |
| Abiraterone Alone May Be as Effective as Combination Therapy for Prostate Cancer | Prostate Cancer | observational | Patients receiving abiraterone alone had a median PSA reduction of 80.2%. | Source → |
| Apalutamide May Help Prostate Cancer Patients Faster Than Abiraterone | Prostate Cancer | observational | Patients initiated on apalutamide were 53% more likely to achieve PSA90 than those initiated on abiraterone acetate within 6 months. | Source → |
| New Combination Therapy Shows Promise for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Median radiographic progression-free survival was 16.6 months in the niraparib + AAP group compared with 10.9 months in the placebo + AAP group. | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration-resistant prostate cancer in patients treated with ABI was significantly longer compared to those treated with DOC (42 vs. 22 months; p = 0.006). | Source → |
| Combining Cancer Drugs May Be More Effective Than Using Them Alone | Prostate Cancer | lab-study | — | Source → |
| Rare Side Effect of Abiraterone Treatment in Prostate Cancer Patients | Prostate Cancer | observational | — | Source → |
| Traditional Chinese Medicine Enhances Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Combining Two Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-1 | Nine participants (33%) showed a 20% or greater decrease in prostate-specific antigen during study treatment. | Source → |
| Triplet Therapy Shows Promise for Prostate Cancer Treatment | Prostate Cancer | meta-analysis | Triplet therapy with darolutamide or abiraterone with docetaxel and ADT improved overall survival, with a hazard ratio of 0.70 (95%CI 0.61-0.80) compared to docetaxel+ADT. | Source → |
| Radiotherapy and Abiraterone Combination for Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Approach to Treatment Prolongs Effectiveness in Prostate Cancer | Prostate Cancer | phase-2 | The study cohort had significantly improved median time to progression (TTP; 33.5 months; p<0.001) and median overall survival (OS; 58.5 months; hazard ratio, 0.41, 95% confidence interval (CI), 0.20-0.83, p<0.001) compared to 14.3 and 31.3 months in the SOC cohort. | Source → |
| Abiraterone and Docetaxel Compared in Prostate Cancer Treatment | Prostate Cancer | observational | The ABI group had a significantly better castration-resistant prostate cancer (CRPC)-free survival than the DOC group [hazard ratio (HR), 0.53; 95% confidence interval (CI), 0.34-0.82]. | Source → |
| Prolactin Levels May Predict Response to Prostate Cancer Treatment | Prostate Cancer | observational | Patients with lower baseline PRL levels responded better to AA than those with higher baseline PRL levels, with a PSA reduction of 66.7% vs. 25.8% (p = 0.001). | Source → |
| Adding Docetaxel or Abiraterone to Prostate Cancer Treatment May Improve Survival | Prostate Cancer | phase-3 | Patients receiving upfront ABI had significantly better CRPCFS than those receiving ADT/CAB or upfront DOC [hazard ratio (HR) 0.39; 95% CI 0.27-0.56]. | Source → |
| Combining Two Compounds May Help Treat Prostate Cancer | Prostate Cancer | lab-study | The combination of abiraterone acetate and apigenin significantly inhibited LNCaP and PC3 cell survival in a manner more marked than observed with either single treatment. | Source → |
| Abiraterone May Be More Effective Than Other Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | The median time to castration resistance was not reached in the abiraterone group, but it was significantly longer than in the other groups. | Source → |
| Combination Therapy Improves Survival in High-Risk Prostate Cancer | Prostate Cancer | meta-analysis | 6-year metastasis-free survival was 82% in the combination-therapy group and 69% in the control group. | Source → |
| Comparing Costs and Adherence to Abiraterone Treatment for Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Comparing Two Cancer Drugs for Advanced Prostate Cancer | Prostate Cancer | observational | — | Source → |
| Comparing Heart Risks of Two Prostate Cancer Treatments | Prostate Cancer | observational | — | Source → |
| Gene Changes in Blood May Predict Prostate Cancer Treatment Outcomes | Prostate Cancer | phase-2 | Plasma tumor DNA detection was associated with shorter overall survival (hazard ratio (HR): 2.89, 95% confidence intervals (CI): 1.77-4.73, P ≤ 0.0001) and progression-free survival (HR: 2.05; 95% CI: 1.36-3.11, P < 0.001). | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.